Newave Pharmaceutical

Executive Summary

Newave Pharmaceutical is a San Diego-based biotechnology company dedicated to discovering and developing novel small molecule antiviral therapies for infectious diseases. Founded in 2018, the company aims to address significant unmet medical needs in virology, leveraging its expertise in small molecule drug discovery. While the company operates in a competitive landscape, its focus on antivirals positions it well given the ongoing global need for effective treatments against emerging and re-emerging viral threats. Early-stage and privately held, Newave has not disclosed funding rounds or pipeline details, but its mission suggests a commitment to advancing preclinical candidates toward clinical development. The success of Newave hinges on its ability to progress its lead programs, secure partnerships, and navigate the rigorous regulatory pathway typical of antiviral drug development.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead Antiviral Candidate40% success
• Q2 2027IND Filing for First Clinical Candidate30% success
• Q1 2027Strategic Partnership or Licensing Agreement50% success